The Effect of Mitomycin C on Superficial Bladder Cancer

Publisher Website
Google Scholar
Abstract
A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg, was evaluated in 16 patients with superficial bladder cancer (stages O and A). Cystoscopically documented tumor was destroyed completely in 11 patients (69%); 3 patients exhibited partial tumor regression. Two patients had only multifocal, grade 3 carcinoma in situ; both had a complete response with negative biopsies and cytology at the 12 wk evaluation. Toxicity was minimal. Further data, including longer followup, are needed to define the potentially promising role of this agent in the over-all management of superficial bladder cancer.